Clinical trials: Neoplasms, Oral
Malignant Melanoma
A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide
The purpose of the study is to determine Efficacy, Safety and Tolerability of MDX-010 (BMS-734016) administered with or without Prophylactic Oral Budesonide.
- Trial name
- NCT00135408
- Testing
- Ipilimumab+ Budesonide
- Where
- 10 sites in United States, Canada and 4 more
- Volunteers
- 115 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumor (Phase 1)
EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors
This the first-in-human (FIH) study for the Investigational Medicinal Product (IMP) EP102, is designed to explore the maximum tolerated dose (MTD), the overall safety profile, its pharmacokinetic (PK) / pharmacodynamic (PD)…
- Trial name
- NCT07163325
- Testing
- EP102
- Where
- 11 sites in Belgium, Czechia and 2 more
- Volunteers
- 48 people
- Sponsor
- Epics Therapeutics
Neoplasms, Cancer
An Open Label Study of Oral Enzastaurin in Participants With Cancer
This study will collect further basic safety data on participants with cancer treated with enzastaurin. This study is not open to the public.
- Trial name
- NCT00309140
- Testing
- enzastaurin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase I
To confirm the safety of BIBF 1120 at a dose level up to 200 mg x 2/day (i.e., overseas recommended Phase III dose for combination treatment) with standard therapy of docetaxel (60 mg/m2 and 75 mg/m2) in Japanese advanced non…
- Trial name
- NCT00876460
- Testing
- BIBF 1120 M + docetaxel M, BIBF 1120 M + docetaxel H, BIBF 1120 H + docetaxel H
- Where
- 2 sites in Japan
- Volunteers
- 43 people
- Sponsor
- Boehringer Ingelheim
Lymphoma
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of Tomivosertib (eFT-508).
- Trial name
- NCT02937675
- Testing
- Tomivosertib (eFT-508)
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Effector Therapeutics
Stomatitis
Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant
CG53135-05, a recombinant human fibroblast growth factor-20 (rhFGF-20) protein, is under investigation for the prevention of oral mucositis.
- Trial name
- NCT00104065
- Testing
- CG53135-05, velafermin
- Where
- 9 sites in United States
- Sponsor
- CuraGen Corporation
Head and Neck Cancer
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer
The purpose of this study is to evaluate the efficacy and safety of palifermin (recombinant human keratinocyte growth factor, rHuKGF) in reducing the incidence of severe oral mucositis in subjects with locally advanced head and…
- Trial name
- NCT00131638
- Testing
- Palifermin
- Volunteers
- 241 people
- Sponsor
- Amgen
Advanced Solid Tumor
The Absorption, Metabolism and Excretion of [14C]CM082 in Human
This is a single-center, open-label, single-dose phase I study to investigate the absorption, metabolism and excretion of [14C] CM082 in healthy Chinese male subjects.
- Trial name
- NCT04434326
- Testing
- [14]CM082 suspension
- Where
- China
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- AnewPharma
Prostatic Neoplasms
A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer
The aim of this study was to evaluate the efficacy of two different doses of BIBF 1120 (250 mg twice daily versus 150 mg twice daily) in an exploratory manner.
- Trial name
- NCT02182063
- Testing
- BIBF 1120 low dose, BIBF 1120 high dose
- Volunteers
- 81 people
- Sponsor
- Boehringer Ingelheim
Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy
The purpose of this study is to determine the feasibility of administering the combination of nilotinib and LDE225 to patients with chronic or accelerated phase of chronic myeloid leukemia and to establish the maximum tolerated…
- Trial name
- NCT01456676
- Testing
- Nilotinib + LDE225
- Where
- 7 sites in Canada, France and 3 more
- Volunteers
- 11 people
- Sponsor
- Novartis Pharmaceuticals
Tumor
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves…
- Trial name
- NCT00413322
- Testing
- belinostat, 5-Fluorouracil (5-FU)
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Valerio Therapeutics
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to determine whether the addition of oral ixazomib to the background therapy of lenalidomide and dexamethasone improves progression free survival (PFS) in participants with relapsed and/or refractory…
- Trial name
- NCT01564537
- Testing
- Ixazomib, Lenalidomide, Dexamethasone
- Where
- 24 sites in United States, Canada
- Volunteers
- 722 people
- Sponsor
- Takeda
Patients With Newly Diagnosed Glioblastoma
A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma
The study objectives are to assess the potential for PLX3397 to improve the efficacy of standard of care radiation therapy (RT) + temozolomide in patients with newly diagnosed glioblastoma (GBM).
- Trial name
- NCT01790503
- Testing
- PLX3397, Radiation Therapy, Temozolomide
- Where
- 9 sites in United States
- Volunteers
- 65 people
- Sponsor
- Daiichi Sankyo
Mouth Diseases
Evaluation of Oral Potentially Malignant Disorders (OPMDs) with STRATICYTE™
The purpose of this study is to validate the ability of the STRATICYTE™ predictive model to predict the transformation of oral potentially malignant disorders (OPMDs) to oral squamous cell carcinoma (OSCC) in a retrospective…
- Trial name
- NCT05853783
- Testing
- STRATICYTE™ Test
- Where
- 5 sites in United States
- Volunteers
- 180 people
- Sponsor
- Proteocyte Diagnostics Inc.
Advanced Nonhematologic Malignancies, Carcinoma, Basal Cell
A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies
This is the first study in which TAK-441 is administered to humans. The patient population will consist of adults aged 18 or older who have advanced nonhematologic malignancies and for whom standard treatment is no longer…
- Trial name
- NCT01204073
- Testing
- TAK-441
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Carcinoma, Renal Cell
VEG111485: A QTc Study of Pazopanib
This is a Phase I, randomized, double-blind, placebo-controlled, study to estimate the effects of daily oral dosing of 800 mg pazopanib on electrocardiographic parameters (QTc interval duration) as compared with placebo in…
- Trial name
- NCT00861029
- Testing
- Pazopanib, Moxifloxacin
- Where
- 8 sites in United States
- Volunteers
- 2 people
- Sponsor
- GlaxoSmithKline
Chronic Myeloid Leukemia, Gastrointestinal Stromal Tumor
A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)
1. Investigational Product 1. Imatinib mesylate tablet 400 mg 2. Glivec film-coated tablet 100 mg (Comparator) 2. Expected target disease 1. chronic myeloid leukemia 2. Gastrointestinal stromal tumors 3.
- Trial name
- NCT01751919
- Testing
- Imatinib mesylate tablet 400 mg, 1 Tablet, Glivec film-coated tablet 100 mg, 4 Tablets
- Where
- South Korea
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Solid Tumor, Adult, Non-hodgkin Lymphoma
First in Human, Dose Escalation, Dose Expansion Study of AUR105
This is a multi-center, open-label, First in Human, Phase 1 study of AUR 105 in adult patients with advanced malignancies. The study will have two parts: a Dose Escalation Part and Dose Expansion Part.
- Conditions
- Solid Tumor, Adult, Non-hodgkin Lymphoma, Hodgkin Lymphoma
- Trial name
- SURYA-1 (NCT05605119)
- Testing
- AUR105
- Where
- 9 sites in India
- Volunteers
- 17 people
- Sponsor
- Aurigene Discovery Technologies Limited
Breast Cancer, Colorectal Cancer
A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED)
This is an investigational study to determine the response rate of relapsed/refractory breast, colorectal and non-small cell lung cancer to oral suberoylanilide hydroxamic acid (SAHA), to evaluate PET as an earlier indicator of…
- Conditions
- Breast Cancer, Colorectal Cancer, Non-small-cell Lung Carcinoma
- Trial name
- NCT00126451
- Testing
- MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA), Duration of Treatment - During each treatment cycle, treatment is administered twice daily for 14 days, followed by 7 days of rest for a total of 10 cycles
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
Cancer Pain
An Efficacy and Safety Study of Hydromorphone Oral Osmotic System (OROS) in Korean Participants With Cancer Pain
The purpose of this is study to evaluate improvement of sleep disorder caused by cancer pain after the administration of Hydromorphone Oral Osmotic System (OROS) in Korean participants with cancer.
- Trial name
- NCT00766831
- Testing
- Hydromorphone
- Volunteers
- 190 people
- Sponsor
- Janssen Korea, Ltd., Korea
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.